Mounjaro
- Product NDC
- 0002-4210
- 11-digit product format
- 000024210
- Labeler code
- 0002
- Product ID
- 0002-4210_08af2d71-07e5-474b-98a2-eb5be9bcf894
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- tirzepatide
- Dosage form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Labeler
- Eli Lilly and Company
- Application
- NDA215866
- Marketing category
- NDA
- Marketing start
- 2026-01-07
- Substance
- TIRZEPATIDE
- Active strength
- 12.5 mg/mL
- Pharmacologic classes
- G-Protein-linked Receptor Interactions [MoA], GLP-1 Receptor Agonist [EPC], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N215866-001 | MOUNJARO (AUTOINJECTOR) | TIRZEPATIDE | 2.5MG/0.5ML (2.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | |
| N215866-002 | MOUNJARO (AUTOINJECTOR) | TIRZEPATIDE | 5MG/0.5ML (5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | |
| N215866-003 | MOUNJARO (AUTOINJECTOR) | TIRZEPATIDE | 7.5MG/0.5ML (7.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | |
| N215866-004 | MOUNJARO (AUTOINJECTOR) | TIRZEPATIDE | 10MG/0.5ML (10MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | |
| N215866-005 | MOUNJARO (AUTOINJECTOR) | TIRZEPATIDE | 12.5MG/0.5ML (12.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | |
| N215866-006 | MOUNJARO (AUTOINJECTOR) | TIRZEPATIDE | 15MG/0.5ML (15MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | |
| N215866-007 | MOUNJARO | TIRZEPATIDE | 2.5MG/0.5ML (2.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | |
| N215866-008 | MOUNJARO | TIRZEPATIDE | 5MG/0.5ML (5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | |
| N215866-009 | MOUNJARO | TIRZEPATIDE | 7.5MG/0.5ML (7.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | |
| N215866-010 | MOUNJARO | TIRZEPATIDE | 10MG/0.5ML (10MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | |
| N215866-011 | MOUNJARO | TIRZEPATIDE | 12.5MG/0.5ML (12.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | |
| N215866-012 | MOUNJARO | TIRZEPATIDE | 15MG/0.5ML (15MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | |
| N215866-013 | MOUNJARO | TIRZEPATIDE | 10MG/2.4ML (4.17MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | |
| N215866-014 | MOUNJARO | TIRZEPATIDE | 20MG/2.4ML (8.33MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | |
| N215866-015 | MOUNJARO | TIRZEPATIDE | 30MG/2.4ML (12.5MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | |
| N215866-016 | MOUNJARO | TIRZEPATIDE | 40MG/2.4ML (16.7MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | |
| N215866-017 | MOUNJARO | TIRZEPATIDE | 50MG/2.4ML (20.8MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | |
| N215866-018 | MOUNJARO | TIRZEPATIDE | 60MG/2.4ML (25MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | |
| N215866-019 | MOUNJARO KWIKPEN | TIRZEPATIDE | 10MG/2.4ML (4.17MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-20 | |
| N215866-020 | MOUNJARO KWIKPEN | TIRZEPATIDE | 20MG/2.4ML (8.33MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-20 | |
| N215866-021 | MOUNJARO KWIKPEN | TIRZEPATIDE | 30MG/2.4ML (12.5MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-20 | |
| N215866-022 | MOUNJARO KWIKPEN | TIRZEPATIDE | 40MG/2.4ML (16.7MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-20 | |
| N215866-023 | MOUNJARO KWIKPEN | TIRZEPATIDE | 50MG/2.4ML (20.8MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-20 | |
| N215866-024 | MOUNJARO KWIKPEN | TIRZEPATIDE | 60MG/2.4ML (25MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-20 |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N215866-001 | 9474780 | 2036-05-13 | U-4374 | Drug substance, Drug product | 2022-06-09 |
| N215866-001 | 11357820 | 2039-06-14 | Drug product | 2022-06-30 | |
| N215866-001 | 12453755 | 2039-06-14 | U-4375 | 2025-11-17 | |
| N215866-001 | 12453755 | 2039-06-14 | U-4376 | 2025-11-17 | |
| N215866-001 | 12453755 | 2039-06-14 | U-4377 | 2025-11-17 | |
| N215866-001 | 12453755 | 2039-06-14 | U-4378 | 2025-11-17 | |
| N215866-001 | 12453755 | 2039-06-14 | U-4379 | 2025-11-17 | |
| N215866-001 | 12453755 | 2039-06-14 | U-4380 | 2025-11-17 | |
| N215866-001 | 12453755 | 2039-06-14 | U-4381 | 2025-11-17 | |
| N215866-001 | 12453755 | 2039-06-14 | U-4382 | 2025-11-17 | |
| N215866-001 | 12453755 | 2039-06-14 | U-4383 | 2025-11-17 | |
| N215866-001 | 12453755 | 2039-06-14 | U-4384 | 2025-11-17 | |
| N215866-001 | 12453755 | 2039-06-14 | U-4385 | 2025-11-17 | |
| N215866-001 | 12453755 | 2039-06-14 | U-4386 | 2025-11-17 | |
| N215866-001 | 12453756 | 2039-06-14 | Drug product | 2025-11-17 | |
| N215866-001 | 12629404 | 2039-06-14 | U-4533 | Drug product | 2026-06-05 |
| N215866-001 | 12629404 | 2039-06-14 | U-4534 | Drug product | 2026-06-05 |
| N215866-001 | 12343382 | 2039-07-22 | U-4229 | 2025-07-25 | |
| N215866-001 | 12343382 | 2039-07-22 | U-4230 | 2025-07-25 | |
| N215866-001 | 12343382 | 2039-07-22 | U-4231 | 2025-07-25 | |
| N215866-001 | 12343382 | 2039-07-22 | U-4232 | 2025-07-25 | |
| N215866-001 | 12343382 | 2039-07-22 | U-4400 | 2025-07-25 | |
| N215866-001 | 12343382 | 2039-07-22 | U-4401 | 2025-07-25 | |
| N215866-001 | 12616740 | 2039-07-22 | U-4500 | 2026-05-05 | |
| N215866-001 | 12616740 | 2039-07-22 | U-4501 | 2026-05-05 | |
| N215866-001 | 12616740 | 2039-07-22 | U-4502 | 2026-05-05 | |
| N215866-001 | 12295987 | 2041-12-30 | U-4192 | 2025-06-11 | |
| N215866-001 | 12295987 | 2041-12-30 | U-4193 | 2025-06-11 | |
| N215866-002 | 9474780 | 2036-05-13 | U-4374 | Drug substance, Drug product | 2022-06-09 |
| N215866-002 | 11357820 | 2039-06-14 | Drug product | 2022-06-30 | |
| N215866-002 | 12453755 | 2039-06-14 | U-4375 | 2025-11-17 | |
| N215866-002 | 12453755 | 2039-06-14 | U-4376 | 2025-11-17 | |
| N215866-002 | 12453755 | 2039-06-14 | U-4377 | 2025-11-17 | |
| N215866-002 | 12453755 | 2039-06-14 | U-4378 | 2025-11-17 | |
| N215866-002 | 12453755 | 2039-06-14 | U-4379 | 2025-11-17 | |
| N215866-002 | 12453755 | 2039-06-14 | U-4380 | 2025-11-17 | |
| N215866-002 | 12453755 | 2039-06-14 | U-4381 | 2025-11-17 | |
| N215866-002 | 12453755 | 2039-06-14 | U-4382 | 2025-11-17 | |
| N215866-002 | 12453755 | 2039-06-14 | U-4383 | 2025-11-17 | |
| N215866-002 | 12453755 | 2039-06-14 | U-4384 | 2025-11-17 | |
| N215866-002 | 12453755 | 2039-06-14 | U-4385 | 2025-11-17 | |
| N215866-002 | 12453755 | 2039-06-14 | U-4386 | 2025-11-17 | |
| N215866-002 | 12453756 | 2039-06-14 | Drug product | 2025-11-17 | |
| N215866-002 | 12629404 | 2039-06-14 | U-4533 | Drug product | 2026-06-05 |
| N215866-002 | 12629404 | 2039-06-14 | U-4534 | Drug product | 2026-06-05 |
| N215866-002 | 12343382 | 2039-07-22 | U-4229 | 2025-07-25 | |
| N215866-002 | 12343382 | 2039-07-22 | U-4230 | 2025-07-25 | |
| N215866-002 | 12343382 | 2039-07-22 | U-4231 | 2025-07-25 | |
| N215866-002 | 12343382 | 2039-07-22 | U-4232 | 2025-07-25 | |
| N215866-002 | 12343382 | 2039-07-22 | U-4400 | 2025-07-25 | |
| N215866-002 | 12343382 | 2039-07-22 | U-4401 | 2025-07-25 | |
| N215866-002 | 12616740 | 2039-07-22 | U-4500 | 2026-05-05 | |
| N215866-002 | 12616740 | 2039-07-22 | U-4501 | 2026-05-05 | |
| N215866-002 | 12616740 | 2039-07-22 | U-4502 | 2026-05-05 | |
| N215866-002 | 12295987 | 2041-12-30 | U-4192 | 2025-06-11 | |
| N215866-002 | 12295987 | 2041-12-30 | U-4193 | 2025-06-11 | |
| N215866-003 | 9474780 | 2036-05-13 | U-4374 | Drug substance, Drug product | 2022-06-09 |
| N215866-003 | 11357820 | 2039-06-14 | Drug product | 2022-06-30 | |
| N215866-003 | 12453755 | 2039-06-14 | U-4375 | 2025-11-17 | |
| N215866-003 | 12453755 | 2039-06-14 | U-4376 | 2025-11-17 | |
| N215866-003 | 12453755 | 2039-06-14 | U-4377 | 2025-11-17 | |
| N215866-003 | 12453755 | 2039-06-14 | U-4378 | 2025-11-17 | |
| N215866-003 | 12453755 | 2039-06-14 | U-4379 | 2025-11-17 | |
| N215866-003 | 12453755 | 2039-06-14 | U-4380 | 2025-11-17 | |
| N215866-003 | 12453755 | 2039-06-14 | U-4381 | 2025-11-17 | |
| N215866-003 | 12453755 | 2039-06-14 | U-4382 | 2025-11-17 | |
| N215866-003 | 12453755 | 2039-06-14 | U-4383 | 2025-11-17 | |
| N215866-003 | 12453755 | 2039-06-14 | U-4384 | 2025-11-17 | |
| N215866-003 | 12453755 | 2039-06-14 | U-4385 | 2025-11-17 | |
| N215866-003 | 12453755 | 2039-06-14 | U-4386 | 2025-11-17 | |
| N215866-003 | 12453756 | 2039-06-14 | Drug product | 2025-11-17 | |
| N215866-003 | 12629404 | 2039-06-14 | U-4533 | Drug product | 2026-06-05 |
| N215866-003 | 12629404 | 2039-06-14 | U-4534 | Drug product | 2026-06-05 |
| N215866-003 | 12343382 | 2039-07-22 | U-4229 | 2025-07-25 | |
| N215866-003 | 12343382 | 2039-07-22 | U-4230 | 2025-07-25 | |
| N215866-003 | 12343382 | 2039-07-22 | U-4231 | 2025-07-25 | |
| N215866-003 | 12343382 | 2039-07-22 | U-4232 | 2025-07-25 | |
| N215866-003 | 12343382 | 2039-07-22 | U-4400 | 2025-07-25 | |
| N215866-003 | 12343382 | 2039-07-22 | U-4401 | 2025-07-25 | |
| N215866-003 | 12616740 | 2039-07-22 | U-4500 | 2026-05-05 |
Orange Book exclusivity#
| Application-product | Exclusivity code | Expiration |
|---|---|---|
| N215866-001 | NCE | 2027-05-13 |
| N215866-001 | NPP | 2028-12-19 |
| N215866-002 | NCE | 2027-05-13 |
| N215866-002 | NPP | 2028-12-19 |
| N215866-003 | NCE | 2027-05-13 |
| N215866-003 | NPP | 2028-12-19 |
| N215866-004 | NCE | 2027-05-13 |
| N215866-004 | NPP | 2028-12-19 |
| N215866-005 | NCE | 2027-05-13 |
| N215866-006 | NCE | 2027-05-13 |
| N215866-007 | NCE | 2027-05-13 |
| N215866-007 | NPP | 2028-12-19 |
| N215866-008 | NCE | 2027-05-13 |
| N215866-008 | NPP | 2028-12-19 |
| N215866-009 | NCE | 2027-05-13 |
| N215866-009 | NPP | 2028-12-19 |
| N215866-010 | NCE | 2027-05-13 |
| N215866-010 | NPP | 2028-12-19 |
| N215866-011 | NCE | 2027-05-13 |
| N215866-012 | NCE | 2027-05-13 |
| N215866-013 | NCE | 2027-05-13 |
| N215866-013 | NPP | 2028-12-19 |
| N215866-014 | NCE | 2027-05-13 |
| N215866-014 | NPP | 2028-12-19 |
| N215866-015 | NCE | 2027-05-13 |
| N215866-015 | NPP | 2028-12-19 |
| N215866-016 | NCE | 2027-05-13 |
| N215866-016 | NPP | 2028-12-19 |
| N215866-017 | NCE | 2027-05-13 |
| N215866-017 | NPP | 2028-12-19 |
| N215866-018 | NCE | 2027-05-13 |
| N215866-018 | NPP | 2028-12-19 |
| N215866-019 | NCE | 2027-05-13 |
| N215866-019 | NPP | 2028-12-19 |
| N215866-020 | NCE | 2027-05-13 |
| N215866-020 | NPP | 2028-12-19 |
| N215866-021 | NCE | 2027-05-13 |
| N215866-021 | NPP | 2028-12-19 |
| N215866-022 | NCE | 2027-05-13 |
| N215866-022 | NPP | 2028-12-19 |
| N215866-023 | NCE | 2027-05-13 |
| N215866-024 | NCE | 2027-05-13 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | MOUNJARO (AUTOINJECTOR) | 2.5MG/0.5ML (2.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-002 | MOUNJARO (AUTOINJECTOR) | 5MG/0.5ML (5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-003 | MOUNJARO (AUTOINJECTOR) | 7.5MG/0.5ML (7.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-004 | MOUNJARO (AUTOINJECTOR) | 10MG/0.5ML (10MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-005 | MOUNJARO (AUTOINJECTOR) | 12.5MG/0.5ML (12.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-006 | MOUNJARO (AUTOINJECTOR) | 15MG/0.5ML (15MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-007 | MOUNJARO | 2.5MG/0.5ML (2.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-008 | MOUNJARO | 5MG/0.5ML (5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-009 | MOUNJARO | 7.5MG/0.5ML (7.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-010 | MOUNJARO | 10MG/0.5ML (10MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-011 | MOUNJARO | 12.5MG/0.5ML (12.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-012 | MOUNJARO | 15MG/0.5ML (15MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-013 | MOUNJARO | 10MG/2.4ML (4.17MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-014 | MOUNJARO | 20MG/2.4ML (8.33MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-015 | MOUNJARO | 30MG/2.4ML (12.5MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-016 | MOUNJARO | 40MG/2.4ML (16.7MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-017 | MOUNJARO | 50MG/2.4ML (20.8MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-018 | MOUNJARO | 60MG/2.4ML (25MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-019 | MOUNJARO KWIKPEN | 10MG/2.4ML (4.17MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-20 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-020 | MOUNJARO KWIKPEN | 20MG/2.4ML (8.33MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-20 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-021 | MOUNJARO KWIKPEN | 30MG/2.4ML (12.5MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-20 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-022 | MOUNJARO KWIKPEN | 40MG/2.4ML (16.7MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-20 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-023 | MOUNJARO KWIKPEN | 50MG/2.4ML (20.8MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-20 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-024 | MOUNJARO KWIKPEN | 60MG/2.4ML (25MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-20 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-001 | MOUNJARO (AUTOINJECTOR) | 2.5MG/0.5ML (2.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-002 | MOUNJARO (AUTOINJECTOR) | 5MG/0.5ML (5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-003 | MOUNJARO (AUTOINJECTOR) | 7.5MG/0.5ML (7.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-004 | MOUNJARO (AUTOINJECTOR) | 10MG/0.5ML (10MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-005 | MOUNJARO (AUTOINJECTOR) | 12.5MG/0.5ML (12.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-006 | MOUNJARO (AUTOINJECTOR) | 15MG/0.5ML (15MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-05-13 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-007 | MOUNJARO | 2.5MG/0.5ML (2.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-008 | MOUNJARO | 5MG/0.5ML (5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-009 | MOUNJARO | 7.5MG/0.5ML (7.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-010 | MOUNJARO | 10MG/0.5ML (10MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-011 | MOUNJARO | 12.5MG/0.5ML (12.5MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-012 | MOUNJARO | 15MG/0.5ML (15MG/0.5ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2023-07-28 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-013 | MOUNJARO | 10MG/2.4ML (4.17MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-014 | MOUNJARO | 20MG/2.4ML (8.33MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-015 | MOUNJARO | 30MG/2.4ML (12.5MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215866-016 | MOUNJARO | 40MG/2.4ML (16.7MG/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2026-01-07 | 011fe1cb6892… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 9474780 | 2036-05-13 | U-4374 | Drug substance, Drug product | 2022-06-09 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 11357820 | 2039-06-14 | Drug product | 2022-06-30 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12453755 | 2039-06-14 | U-4375 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12453755 | 2039-06-14 | U-4376 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12453755 | 2039-06-14 | U-4377 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12453755 | 2039-06-14 | U-4378 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12453755 | 2039-06-14 | U-4379 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12453755 | 2039-06-14 | U-4380 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12453755 | 2039-06-14 | U-4381 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12453755 | 2039-06-14 | U-4382 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12453755 | 2039-06-14 | U-4383 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12453755 | 2039-06-14 | U-4384 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12453755 | 2039-06-14 | U-4385 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12453755 | 2039-06-14 | U-4386 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12453756 | 2039-06-14 | Drug product | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12629404 | 2039-06-14 | U-4533 | Drug product | 2026-06-05 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12629404 | 2039-06-14 | U-4534 | Drug product | 2026-06-05 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12343382 | 2039-07-22 | U-4401 | 2025-07-25 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12343382 | 2039-07-22 | U-4229 | 2025-07-25 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12343382 | 2039-07-22 | U-4230 | 2025-07-25 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12343382 | 2039-07-22 | U-4231 | 2025-07-25 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12343382 | 2039-07-22 | U-4232 | 2025-07-25 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12343382 | 2039-07-22 | U-4400 | 2025-07-25 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12616740 | 2039-07-22 | U-4500 | 2026-05-05 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12616740 | 2039-07-22 | U-4501 | 2026-05-05 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12616740 | 2039-07-22 | U-4502 | 2026-05-05 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12295987 | 2041-12-30 | U-4192 | 2025-06-11 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | 12295987 | 2041-12-30 | U-4193 | 2025-06-11 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-002 | 9474780 | 2036-05-13 | U-4374 | Drug substance, Drug product | 2022-06-09 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-002 | 11357820 | 2039-06-14 | Drug product | 2022-06-30 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-002 | 12453755 | 2039-06-14 | U-4376 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-002 | 12453755 | 2039-06-14 | U-4383 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-002 | 12453755 | 2039-06-14 | U-4379 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-002 | 12453755 | 2039-06-14 | U-4375 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-002 | 12453755 | 2039-06-14 | U-4380 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-002 | 12453755 | 2039-06-14 | U-4382 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-002 | 12453755 | 2039-06-14 | U-4377 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-002 | 12453755 | 2039-06-14 | U-4381 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-002 | 12453755 | 2039-06-14 | U-4384 | 2025-11-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215866-002 | 12453755 | 2039-06-14 | U-4385 | 2025-11-17 | caaa826d4ba7… |
Observed Orange Book exclusivity history#
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-001 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-002 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-002 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-003 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-003 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-004 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-004 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-005 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-006 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-007 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-007 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-008 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-008 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-009 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-009 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-010 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-010 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-011 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-012 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-013 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-013 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-014 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-014 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-015 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-015 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-016 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-016 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-017 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-017 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-018 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-018 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-019 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-019 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-020 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-020 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-021 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-021 | NPP | 2028-12-19 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-022 | NCE | 2027-05-13 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215866-022 | NPP | 2028-12-19 | caaa826d4ba7… |
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Mounjaro
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| TIRZEPATIDE | 12.5 mg/mL |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| OYN3CCI6QE | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 2601743 | Internal RxNorm lookup |
| 2601746 | Internal RxNorm lookup |
| 2601755 | Internal RxNorm lookup |
| 2601758 | Internal RxNorm lookup |
| 2601761 | Internal RxNorm lookup |
| 2601764 | Internal RxNorm lookup |
| 2601767 | Internal RxNorm lookup |
| 2601770 | Internal RxNorm lookup |
| 2601773 | Internal RxNorm lookup |
| 2601776 | Internal RxNorm lookup |
| 2601784 | Internal RxNorm lookup |
| 2601785 | Internal RxNorm lookup |
| 2644396 | Internal RxNorm lookup |
| 2644399 | Internal RxNorm lookup |
| 2644401 | Internal RxNorm lookup |
| 2644403 | Internal RxNorm lookup |
| 2644405 | Internal RxNorm lookup |
| 2644407 | Internal RxNorm lookup |
| 2644409 | Internal RxNorm lookup |
| 2644411 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 764832a6-c731-479b-b340-b4c8813a2a29 | Product name | 1 | 20250724 |
| 079c774f-6797-40bd-b11b-fd311f893a4e | Product name | 1 | 20230124 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0002-4210-01 | Mounjaro | 2.4 mL in 1 VIAL, MULTI-DOSE | INJECTION, SOLUTION | 2.4 | 38 | |
| 0002-4210-11 | Mounjaro | 1 in 1 CARTON | INJECTION, SOLUTION | 1 | 38 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| MOUNJARO | TIRZEPATIDE | A-S Medication Solutions | 78b268b4-9215-44b4-b565-fcec315d027c | 2026-07-29 | Boxed warning, Warnings, Adverse reactions | 215866 NDA215866 |
| MOUNJARO | TIRZEPATIDE | A-S Medication Solutions | c1ceb7ca-9976-4ac1-b45c-3975de8aac4c | 2026-07-29 | Boxed warning, Warnings, Adverse reactions | 215866 NDA215866 |
| MOUNJARO | TIRZEPATIDE | A-S Medication Solutions | 78aad975-4971-49fa-b4b0-6aa39f76d2e7 | 2026-07-29 | Boxed warning, Warnings, Adverse reactions | 215866 NDA215866 |
| MOUNJARO | TIRZEPATIDE | A-S Medication Solutions | 7dd5ae1d-2156-44c1-a2d0-4be1bc76420e | 2026-07-29 | Boxed warning, Warnings, Adverse reactions | 215866 NDA215866 |
| MOUNJARO | TIRZEPATIDE | A-S Medication Solutions | f4edc99a-ecdb-4a68-bcb4-69fbba2190e8 | 2026-07-29 | Boxed warning, Warnings, Adverse reactions | 215866 NDA215866 |
| MOUNJARO | TIRZEPATIDE | A-S Medication Solutions | 0818426a-53eb-4db7-9609-bbae1e7a3964 | 2026-07-29 | Boxed warning, Warnings, Adverse reactions | 215866 NDA215866 |
| Mounjaro | TIRZEPATIDE | Eli Lilly and Company | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 2026-04-22 | Boxed warning, Warnings, Adverse reactions | 215866 NDA215866 0002-4210 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 2601770 | mounjaro 10 MG in 0.5 ML Auto-Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644419 | mounjaro 10 MG in 0.5 ML Injection | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2735292 | mounjaro 10 MG per dose (40 MG in 2.4 ML) Pen Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601776 | mounjaro 12.5 MG in 0.5 ML Auto-Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644415 | mounjaro 12.5 MG in 0.5 ML Injection | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2735294 | mounjaro 12.5 MG per dose (50 MG in 2.4 ML) Pen Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2733666 | mounjaro 12.5 MG/ML Injectable Solution | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601758 | mounjaro 15 MG in 0.5 ML Auto-Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644411 | mounjaro 15 MG in 0.5 ML Injection | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2735297 | mounjaro 15 MG per dose (60 MG in 2.4 ML) Pen Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2733668 | mounjaro 16.7 MG/ML Injectable Solution | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601764 | mounjaro 2.5 MG in 0.5 ML Auto-Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644407 | mounjaro 2.5 MG in 0.5 ML Injection | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2735286 | mounjaro 2.5 MG per dose (10 MG in 2.4 ML) Pen Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2733670 | mounjaro 20.8 MG/ML Injectable Solution | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2733671 | mounjaro 25 MG/ML Injectable Solution | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2733673 | mounjaro 4.17 MG/ML Injectable Solution | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601746 | mounjaro 5 MG in 0.5 ML Auto-Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644403 | mounjaro 5 MG in 0.5 ML Injection | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2735288 | mounjaro 5 MG per dose (20 MG in 2.4 ML) Pen Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601785 | mounjaro 7.5 MG in 0.5 ML Auto-Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644399 | mounjaro 7.5 MG in 0.5 ML Injection | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2735290 | mounjaro 7.5 MG per dose (30 MG in 2.4 ML) Pen Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2733675 | mounjaro 8.33 MG/ML Injectable Solution | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601767 | tirzepatide 10 MG in 0.5 ML Auto-Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644417 | tirzepatide 10 MG in 0.5 ML Injection | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2734628 | tirzepatide 10 MG per dose (40 MG in 2.4 ML) Pen Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601773 | tirzepatide 12.5 MG in 0.5 ML Auto-Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644413 | tirzepatide 12.5 MG in 0.5 ML Injection | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2734632 | tirzepatide 12.5 MG per dose (50 MG in 2.4 ML) Pen Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2732437 | tirzepatide 12.5 MG/ML Injectable Solution | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601755 | tirzepatide 15 MG in 0.5 ML Auto-Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644409 | tirzepatide 15 MG in 0.5 ML Injection | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2734636 | tirzepatide 15 MG per dose (60 MG in 2.4 ML) Pen Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2732442 | tirzepatide 16.7 MG/ML Injectable Solution | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601761 | tirzepatide 2.5 MG in 0.5 ML Auto-Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644405 | tirzepatide 2.5 MG in 0.5 ML Injection | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2734640 | tirzepatide 2.5 MG per dose (10 MG in 2.4 ML) Pen Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2732446 | tirzepatide 20.8 MG/ML Injectable Solution | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2732449 | tirzepatide 25 MG/ML Injectable Solution | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2732452 | tirzepatide 4.17 MG/ML Injectable Solution | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601743 | tirzepatide 5 MG in 0.5 ML Auto-Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644401 | tirzepatide 5 MG in 0.5 ML Injection | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2734644 | tirzepatide 5 MG per dose (20 MG in 2.4 ML) Pen Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601784 | tirzepatide 7.5 MG in 0.5 ML Auto-Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644396 | tirzepatide 7.5 MG in 0.5 ML Injection | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2734623 | tirzepatide 7.5 MG per dose (30 MG in 2.4 ML) Pen Injector | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2732456 | tirzepatide 8.33 MG/ML Injectable Solution | PSN | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601746 | 0.5 ML tirzepatide 10 MG/ML Auto-Injector [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644403 | 0.5 ML tirzepatide 10 MG/ML Injection [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601785 | 0.5 ML tirzepatide 15 MG/ML Auto-Injector [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644399 | 0.5 ML tirzepatide 15 MG/ML Injection [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601770 | 0.5 ML tirzepatide 20 MG/ML Auto-Injector [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644419 | 0.5 ML tirzepatide 20 MG/ML Injection [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601776 | 0.5 ML tirzepatide 25 MG/ML Auto-Injector [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644415 | 0.5 ML tirzepatide 25 MG/ML Injection [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601758 | 0.5 ML tirzepatide 30 MG/ML Auto-Injector [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644411 | 0.5 ML tirzepatide 30 MG/ML Injection [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601764 | 0.5 ML tirzepatide 5 MG/ML Auto-Injector [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644407 | 0.5 ML tirzepatide 5 MG/ML Injection [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2735290 | 2.4 ML tirzepatide 12.5 MG/ML Pen Injector [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2735292 | 2.4 ML tirzepatide 16.7 MG/ML Pen Injector [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2735294 | 2.4 ML tirzepatide 20.8 MG/ML Pen Injector [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2735297 | 2.4 ML tirzepatide 25 MG/ML Pen Injector [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2735286 | 2.4 ML tirzepatide 4.17 MG/ML Pen Injector [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2735288 | 2.4 ML tirzepatide 8.33 MG/ML Pen Injector [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2733666 | tirzepatide 12.5 MG/ML Injectable Solution [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2733668 | tirzepatide 16.7 MG/ML Injectable Solution [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2733670 | tirzepatide 20.8 MG/ML Injectable Solution [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2733671 | tirzepatide 25 MG/ML Injectable Solution [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2733673 | tirzepatide 4.17 MG/ML Injectable Solution [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2733675 | tirzepatide 8.33 MG/ML Injectable Solution [Mounjaro] | SBD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601743 | 0.5 ML tirzepatide 10 MG/ML Auto-Injector | SCD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644401 | 0.5 ML tirzepatide 10 MG/ML Injection | SCD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601784 | 0.5 ML tirzepatide 15 MG/ML Auto-Injector | SCD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644396 | 0.5 ML tirzepatide 15 MG/ML Injection | SCD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601767 | 0.5 ML tirzepatide 20 MG/ML Auto-Injector | SCD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644417 | 0.5 ML tirzepatide 20 MG/ML Injection | SCD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2601773 | 0.5 ML tirzepatide 25 MG/ML Auto-Injector | SCD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
| 2644413 | 0.5 ML tirzepatide 25 MG/ML Injection | SCD | d2d7da5d-ad07-4228-955f-cf7e355c8cc0 | 38 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 0002-4210-01 | 00002421001 | 2.4 mL in 1 VIAL, MULTI-DOSE | 2.4 ml | Historical | |||
| 0002-4210-11 | 00002421011 | 1 VIAL, MULTI-DOSE in 1 CARTON (0002-4210-11) / 2.4 mL in 1 VIAL, MULTI-DOSE (0002-4210-01) | 2026-01-07 | No | No | Current |